Method for determining donor kidneys' suitability for transplantation may be flawed

Highlight

• Results from biopsies taken when kidneys were procured from donors were not reliable for determining whether the organs were suitable for transplantation.

Washington, DC (October 25, 2018) -- New research indicates that many kidneys obtained for transplantation from deceased donors are not being used because of biopsy findings despite their unreliability and reproducibility. The findings, which appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN) and will be published at ASN Kidney Week 2018, may suggest an urgent need to re-examine the role of such biopsies in the allocation of kidneys.

Kidneys obtained from deceased donors for transplantation are a scarce and valuable resource, yet 20% of kidneys are discarded--most commonly due to findings noted on biopsies taken when the kidney is procured from the donor. Such procurement biopsies are often read by pathologists with limited training or experience in pathology of the kidney.

To study the predictive value and reproducibility of procurement biopsies for deciding which kidneys should be transplanted and which should be discarded, a team led by Sumit Mohan, MD, MPH and S. Ali Husain, MD, MPH (Columbia University Vagelos College of Physicians and Surgeons and the Mailman School of Public Health) examined information on nearly 300 deceased-donor kidneys that were transplanted at their institution from 2006-2009. The organs had undergone both a procurement biopsy and a reperfusion biopsy, the gold standard as it is done as a core needle biopsy read by an experienced pathologist using paraffin embedded tissue and multiple stains.

The investigators found that the agreement between the procurement biopsies and the reperfusion biopsies was poor. Also, the procurement biopsies were not as accurate as reperfusion biopsies for predicting transplant success after organs were transplanted into patients. The researchers also studied a subset of 116 kidneys that underwent more than one procurement biopsy during the allocation process, and they found significant disagreement between sequential procurement biopsies on the same kidney, underscoring the poor reproducibility of the procurement biopsy.

"Limited reliance on procurement biopsy histology will likely result in an improvement in organ utilization by reducing the discard of kidneys attributable to these findings," said Dr. Mohan. "This has the potentially to improve organ allocation efficiency and dramatically increase the number of kidney transplants being performed in the United States."

The investigators noted that efforts to improve the predictive value of biopsies could include requiring biopsy review by experienced kidney pathologists, standardizing biopsy techniques and biopsy reporting, and better integrating biopsy data with other clinical information. "We believe that prospective and randomized studies are needed to definitively understand the role of procurement biopsies, if any, in efficient and appropriate organ allocation and utilization," said Dr. Husain.

###

Study co-authors include Dustin Carpenter, MD, Corey Brennan, MPH, Ibrahim Batal, MD, Isaac E. Hall, MD, Dominick Santoriello, MD, Raphael Rosen, MD, R. John Crew, MD, Eric Campenot, MD, Geoffrey K. Dube, MD, Jai Radhakrishnan, MD, MS, M. Barry Stokes, MD, P. Rodrigo Sandoval, MD, Vivette D'Agati, MD, David J. Cohen, MD, Lloyd E. Ratner, MD, MPH, and Glen Markowitz, MD.

Disclosures: Dr. Husain is supported by the Young Investigator Award from the National Kidney Foundation and Dr. Mohan is supported by the NIH/NIDDK and the Arnold Foundation/American Society of Transplantation

The article, entitled "Procurement Biopsies in the Evaluation of Deceased Donor Kidneys," will appear online at http://cjasn.asnjournals.org/ on October 25, 2018, doi: 10.2215/CJN.04150418, and will be presented at ASN Kidney Week 2018 during a session entitled, "Best of ASN Journals: CJASN and JASN".

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 131 countries. For more information, please visit http://www.asn-online.org or contact the society at 202-640-4660.

---

---